Taranabant, a novel cannabinoid type 1 receptor inverse agonist

Bradley A Fremming, S. T. Boyd

Research output: Contribution to journalReview article

11 Scopus citations


Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.

Original languageEnglish (US)
Pages (from-to)1116-1129
Number of pages14
JournalCurrent Opinion in Investigational Drugs
Issue number10
Publication statusPublished - Oct 7 2008


ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this